$3.51
4.46% yesterday
Nasdaq, Apr 25, 10:15 pm CET
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Iovance Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell ther...
Neutral
The Motley Fool
3 days ago
Iovance Biotherapeutics (IOVA 4.38%) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic melanoma.
Positive
The Motley Fool
7 days ago
Picking stocks with a relatively narrow timeframe in mind -- and with a particular performance expectation -- can be tricky. Most investors can distinguish between bad, good, and even-better investment prospects.
Neutral
GlobeNewsWire
8 days ago
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 17, 2025 (the “Date of Grant”), the Company approved the grant of induce...
Neutral
The Motley Fool
12 days ago
Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money.
Positive
The Motley Fool
19 days ago
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Positive
The Motley Fool
about one month ago
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval of a key therapy -- its shares have significantly lagged the market.
Positive
The Motley Fool
about one month ago
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today